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Drug Matrix cell E4 Treatment systems: Psychosocial therapies
S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
K  Forging inter-service l inks  in US states  (2012). Implementing psychosocial  approaches  to promoting patient trans ition between services  involved inter-
organisational  and operational  analyses  that forged stronger service networks  and identi fied gaps  in the continuum of care. Si ting case managers  at
detoxi fication services  has  been (2006) one successful  l inkage tactic.
K  De-individual isation forced by cost-containment seems bad for patients  (2008). Us ing advanced methods, this  US study found that compared to the average,
substance use was worse after treatment at centres  constrained by funders  in the services  they could offer and in their abi l i ty to individual ise treatment, but better
in those subject to qual i ty accreditation.
K  In UK active referral  improves  NA/AA attendance but not abstinence (2012). Tests  the ambition to extend recovery beyond formal  treatment by systematical ly
l inking patients  to mutual  a id groups. Being encouraged by ei ther a  doctor or a  peer (especial ly the latter) substantia l ly improved attendance at 12-step groups,
but impacts  on abstinence were much smal ler and not statistical ly s igni ficant. Corresponding US study below.
K  Active and pers istent l ink attempts  enhance mutual  a id engagement (2007). Showed in the US context that pers istent and practical  efforts  can strengthen 12-step
group involvement after treatment and modestly improve substance use outcomes. Corresponding Bri tish study above.
K  Determining who needs res identia l  care (2001). US study’s  cri teria  and the methods used to develop them offer a  way to reserve res identia l  rehabi l i tation for
those who need i t, improving treatment completion rates  for both res identia l  and non-res identia l  options.
R  Implementing continuing care interventions  (2011). Psychosocial  s trategies  to help ensure patients  who need i t receive long-term care or aftercare.
R  Peer-based recovery support services  (2009). Compendious  review for (among others) planners  and commiss ioners  of services  whose distinctive strategy is  to
improve l inkage to mutual  a id groups and other peer-based recovery support resources. Also reviews l i terature on peer-based support i tsel f.
R  Varieties  and impact of case management (2006). An expert Euro-US col laboration examines  a  core mechanism for transforming isolated episodes  of care into
coherently staged and comprehensive reintegration programmes – someone who remains  a  stable hub orchestrating di fferent phases  of service del ivery. See also
US guidance below.
R  Only severe cases  di fferentia l ly benefi t from res identia l  care (2003). Notes  from Drug and Alcohol  Findings  on studies  comparing res identia l  with non-
res identia l  treatment concludes  that for patients  who accept and can safely be sent to ei ther, there is  l i ttle to choose between them. Severe cases  may however
di fferentia l ly benefi t from res identia l  care. This  i s  an informal  account not peer-reviewed. See also a  Cochrane review (2006) l imited to randomised tria ls  of
therapeutic communities  for substance-related disorders .
G  Commiss ioning for recovery ([UK] National  Treatment Agency for Substance Misuse, 2010). Includes  recommended psychosocial  services  and l inkages  to mutual
aid networks.
G  Implementing NICE-recommended psychosocial  interventions  (National  Treatment Agency for Substance Misuse, 2010). Commiss ioned from Bri tish
Psychological  Society; offers  framework for planning, commiss ioning, developing ski l l s  and auditing provis ion in relation to psychosocial  interventions
recommended by the UK’s  health service improvement authori ty.
G  Setting up a local  treatment system ([UK] Department of Health and National  Treatment Agency for Substance Misuse, 2006). ‘Pre-recovery’ guidance for local
health organisations  and their partners  on del ivering a  coherently planned and integrated treatment system for adult problem drug users .
G  Coordinating services  to meet individual  needs  ([UK] National  Treatment Agency for Substance Misuse, 2007). Guidance on care planning and care coordination
(“the processes  that need to be in place to ensure that drug treatment [and other] services  work together effectively to meet service users ’ individual  needs”) based
on the good practice identi fied in a  national  review of the performance of treatment commiss ioning bodies  in England.
G  Integrated care for drug or a lcohol  users  (Report Produced for the Scottish Advisory Committee on Drug Misuse, 2008). Treatment system guidance for Scotland.
G  Organis ing hol istic and continuing care ([US] Substance Abuse and Mental  Health Services  Administration, 1998). US consensus  guidance on case management
to orchestrate the range of services  often needed to promote lasting and multi -faceted recovery. See also review above.
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page and hot topics  on computerised therapy and advice and res identia l  rehabi l i tation.
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What is this cell about? The roles of ‘psychosocial’ therapies (ranging from brief advice and counselling to extended therapies based on
psychological theories) in systems for treating drug use problems implemented across an administrative area. In particular, their role in
creating a cost-effective mix of services which offers patients/clients attractive access points and appropriate options for moving
between services or using them in parallel. Involves commissioning, contracting and purchasing decisions to meet local needs in the
context of resource constraints and national policy. At this distance from the preoccupation with intervention effectiveness, research is
scarce, and rarely of the ‘gold standard’ randomised controlled trial format, but we can fall back on studies and reviews which deal with
similar issues across treatment, not just in relation to psychosocial interventions.
Where should I start? William White’s monograph on peer-based recovery support (through mutual aid groups – most commonly, 12-
step – and other resources) is typically meticulous and comprehensively researched, yet cogently written. Its importance is that these
low-cost or free resources seem the only feasible way to square the circle of doing more with less – reconciling diminished resources
with bringing more patients to the point where they can leave treatment, achieve wide-ranging, whole-life recovery, not just remission
from dependence, yet avoid life-, health-, and crime-threatening relapse. Apart from cost, peer support’s virtues include potentially life-
long support available 24 hours a day, and possibly too self-empowerment not naturally promoted by the roles of ‘patient’ or ‘client’.
The monograph comes from (see his collected writings) someone who more than any other has promoted the recovery movement and
provided its scholarly underpinnings, helping contextualise treatment as often merely the first step to the prolonged “recovery
maintenance” advocated by the US expert now advising Public Health England on addiction treatment. In this vision, the focus shifts to
systems around the clinic within which the patient must eventually reshape their life in community with others who have done or are
trying to do the same, secured by ties to family, community, and work. Peer-based support is an essential element within what William
White has described as ‘recovery-oriented systems of care’.
Highlighted study Much has been built on a US study which showed that if they try hard and smartly enough, services can profitably
direct patients to continuing support from mutual aid groups. Based on six-month outcomes, it was the only study cited by NICE which
could directly support its recommendation that for patients who have expressed an interest, “staff should consider facilitating ... initial
contact with the [12-step] group, for example by making the appointment, arranging transport, accompanying him or her to the first
session and dealing with any concerns.” In similar vein, national recovery-oriented commissioning
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guidance advised “local partnerships [to] promote access to relevant mutual aid networks.” Since those
documents were written there has been a corresponding British study.
Let’s see if the evidence stacks up. Check the Findings analysis of the US study’s 12-month outcomes.
Though worthwhile, impacts of intensive referral to 12-step groups versus merely being encouraged to
go were modest  first chart; another 10% former patients abstinent from alcohol and drugs (51% v.
41%) and small extra reductions in drug-related (as well as drink-related) problems. These gains
emerged in circumstances which should have maximised the impact of intensive referral.
Now the UK study. The general picture was that being encouraged by either a doctor or a peer
(especially the latter) substantially improved attendance at 12-step groups, but resulting impacts on
abstinence were much smaller and not statistically significant  second chart. This contrast calls in to
question whether post-treatment attendance ‘artifically’ elevated by special efforts during treatment
has a substantial impact on later abstinence. Rather than 12-step attendance fostering abstinence, the
results seem more consistent with its being a marker of the pre-existing ability and determination to sustain abstinence. But as our
commentary points out, that assessment is based on a study which trialled a very modest single-session
intervention without follow-up sessions or escorts to meetings, and assessed its impact with a single,
limited measure of substance use among a small group of patients from one unit over a short time period.
The study was not intended as a definitive test of what intensive intervention might be able to achieve in
Britain.
The other two studies cited in the commentary on the US study both dealt with drinkers being referred to
AA groups. In one, extensive encouragement to attend did somewhat promote abstinence, but alcohol-
related problems and heavy drinking were unaffected. In the second, it made no overall difference,
because some patients responded better to extended AA-focused counselling, others to just being told to
go.
So perhaps the messages are to individualise and not to expect too much even from extensive attempts to
promote mutual aid groups. When groups are abstinence-based, such efforts may end in some patients
attending and opting for abstinence, but sometimes only instead of other routes to remission. One very
important point though: lack of strong evidence for ‘x’ does not mean, ‘Do not do x,’ if it makes sense, costs little, may help some, and is
unlikely to harm others.
Issues to think about
 How much should be left to services? What should commissioners specify in their tenders and agreements with services, and what
should they leave to clinical staff in the services? That is of course an issue for treatment of any kind, but is most pertinent in
psychosocial therapies. Medications have to be adjusted to the individual, but there are accepted schedules and known effects and side
effects, and acknowledged experts in the forms of doctors and pharmacists. For counselling and psychosocial therapies, there are of
course professional boundaries, unacceptable ways of treating clients, and the need for a well structured, monitored and supervised
approach. But within such limits, when it comes to the content of the intervention and what approach to take with an individual, beyond
the generalities of the ‘common factors’ introduced in cell A4’s bite (and qualities like empathy are hard to contractually require) there
seem few rules which should not sometimes be broken. It is not even the case that qualified ’experts’ do better on average than
‘counsellors by experience’. Yet if commissioners leave content and approach to the service, they have no direct control over these
aspects of the quality and nature of the services they are responsible for and risk patients being short-changed; if they specify too tightly
or on inappropriate dimensions, they risk counterproductively restricting creativity, responsiveness and individualisation. Where do you
stand on this dilemma?
 Who needs residential care? That may seem a straightforward question tailor-made for a scientifically objective answer; you will have
guessed that is not the case. Nevertheless, there is some science to inform those answers, notably the US study which developed a
‘decision-tree’ indicating who is likely to benefit most from a therapeutic community programme offered either on a residential, or a non-
residential basis. It was one of the very few studies not just to record who benefits most, but to have tested how this information might
be used to guide allocation.
Check our analysis and you will see that first the protocol excluded patients who must be allocated to either setting on practical or safety
grounds, then chose residential care for patients least likely to be able to sustain their recovery due to their past record and their lack of
critical elements of what today we call ‘recovery capital’. The result was that patients were 60% more likely to have been retained or
completed treatment if they were matched to settings according to these criteria than if they were not, and the advantage was seen in
those allocated to non-residential as well as residential care; residential care was not universally preferable. Note that in this study the
protocol would have allocated 8 in 10 patients to residential care.
For more research turn to this informal Findings review comparing outcomes from residential and non-residential care, and this highly
formal review which did the same (and more) specifically in relation to therapeutic communities. The former gains in breadth for what it
might lack in rigour, the latter suffers from a dearth of studies due to selecting only randomised controlled trials. Such studies must
select patients who can safely and practically be sent to either option, yet still over half did not start their allotted treatments, being
considered unsuitable by the service or failing to attend. As well as undermining the studies, this was perhaps a sign that often is not
feasible to decide who goes where by a virtual flip of a coin, when the settings are so different and require such different forms of
commitment from the patients. It was one of the reasons why the Cochrane review was unable to conclude anything much – itself
important, because it leaves no convincing reason to deploy the more expensive residential setting as a frontline alternative to non-
residential care.
Prepared to walk on methodologically shakier ground, the Findings review got further, but at the cost of also not being able to be definite
in its conclusions – which were that residential settings seem to help extricate residents from particularly damaging environments, but
also that the added benefits can fade after discharge back to those environments. In some studies people at risk of suicide and those
with relatively severe psychiatric problems, perhaps combined with severe employment or family problems, particularly benefited from
residential settings, supporting the common belief that these differentially benefit more severely dependent and multiply problematic
clients.
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So much for the science, what of other considerations? From this Effectiveness Bank hot topic we learn that providers of residential care
in the UK have joined forces in the face of what they see as the drastic under-use of their services. In badging themselves providers of
“full recovery”, they decisively entered the contested territory (explored in cell A2’s bite) of just what recovery is, let alone how the ‘full’
version differs from any other. Their ambition for a more frontline status for residential care seems contradicted by heavyweight and
unambiguous guidance from NICE, the UK’s authority on evidence-based ways to improve health and social care. NICE’s experts advised
that residential treatment be reserved for substance users with “significant comorbid physical, mental health or social (for example,
housing) problems”, who should also have “not benefited from previous community-based psychosocial treatment”.
The implication is that even the highly vulnerable cases referred to residential services must first have tried and done poorly in non-
residential options, perhaps risking life-threatening relapse and a possibly extended addiction career which might have ended sooner.
Critics of NICE’s ‘last resort’ position argue that the reason why some clients are in such poor mental, physical and/or social states is that
residential rehabilitation had been denied them earlier in their drug using careers, when they had a greater chance of succeeding before
the deterioration became too deep. An opposing argument is that at the level of an individual, predicting for whom non-residential care
will fail is such an imprecise science that ‘suck it and see’ is the only realistic strategy; trying residential services first risks unnecessary
expenditure which would drain treatment resources.
In practice, according to an analysis for what was England’s national addiction treatment authority, residential rehabilitation is very rarely
used, and rather than full recovery, a spell in ‘rehab’ ends for 7 in 10 with drop out from treatment or the need for further treatment. But
to return to the paragraph above, perhaps that is due to last-resort policies reserving residential rehabilitation for the most needy clients
– and perhaps too, if half these residents have later (even if with further help) been able to leave treatment no longer dependent, that is
a good record. Set against this is that while referrers to residential rehabilitation might select for severity, either directly or because of
the hurdles applicants have to clamber over to get funded, they also select the most highly motivated drug users prepared to do what it
takes to get placed somewhere away from home and out of reach of drugs to try for abstinence.
Now perhaps you see more clearly (if you did not already) why – as with the opposite treatment pole, methadone maintenance – science
can only inform, not decide these issues. Think through the origins of your feelings about what the role of residential care should be; how
much does your stance its proper extent and targeting rely on research, how much on experience – perhaps your own as a service user –
how much on affection for one or other type of service, how much on values – and how much on cost?
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